Since 2 years, we saw AI (Artificial Intelligence) spreading in more and more domains, sometime presented as the “panacée” of all problems. In healthcare, and especially in drug discovery, many announces are done but, to be honest, very few results are published. In the article, the author explains the advantages of using IA, in particular at the earliest steps of drug discovery. But, he also explains constraints and limits of these uses.
Even then, no drug is likely to come from AI alone. “What AI and machine learning promise to do is not magic,” Khalil explains. “It promises to help automate what we can learn from data, and I don’t think there is a pharma company out there that does not want that.”Iya Khalil – Co-founder of GNS Healthcare
In HCS Pharma, we use AI to improve our pictures analyzing capacities. Our first results with machine learning are very promising and we are associated to a doctoral position that will be opened next September on this topic. If you are interested in this field, feel free to contact us!